Voxelotor (Oxbryta®) – Haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years.
|Pharm. company||Global Blood Therapeutics Germany GmbH|
|G-BA procedure ID||2022-05-15-D-813|
|ICD-10 codes||D57.0Sickle-cell disease NOS with crisis, D57.1Hb-SS disease without crisis|
|Therapeutic area||Hematopoietic diseases ORPHAN|
|Reason for procedure||Initial assessment|
|G-BA resolution "Anwendungsgebiet des Beschlusses" (German)|
Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in
adults and paediatric patients 12 years of age and older as monotherapy or in combination with
|Oxbryta is used in adults, children and adolescents aged 12 and over for the treatment of haemolytic anaemia due to sickle cell disease as a monotherapy or in combination with hydroxycarbamide.||– (Orphan drug)|
9. Associated procedures
|Resolution||INN||Brand name||Indication||Patients||Additional benefit|
|15.05.2022 – 03.11.2022||Voxelotor||Oxbryta®||Haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years.||1,590 – 2,580|
<< List of all resolutions
The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.